论文部分内容阅读
目的:研究黄芩苷抑制静脉桥术后内膜斑块形成的作用及其机理。方法:通过建立动脉粥样硬化兔模型,在此基础上建立颈外静脉-颈总动脉移植模型,试验过程中用黄芩苷进行干预,同期用西药非诺贝特进行对照干预。通过对血清总胆固醇(TC)、低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、丙二醛(MDA)、超氧化物歧化酶(SOD)含量的测定,及斑块面的积评估,观察黄芩苷在调节血脂、抗动脉粥样硬化、抗氧化及抑制斑块形成作用的作用并探讨其机理。结果:中药组(黄芩苷)与西药组(非诺贝特)比较,血清总胆固醇、低密度胆固醇含量明显低于西药组(P<0.05);有效降低MDA水平,提升SOD水平(P<0.05),且呈剂量依赖关系,黄芩苷给药浓度越高,上述作用更明显。结论:黄芩苷具有调节血脂、抗动脉粥样硬化、抗氧化及抑制斑块形成,从而起到抑制静脉桥再狭窄的作用,为中医药治疗冠状动脉旁路移植术后静脉桥再狭窄提供有力科学依据。
Objective: To study the effect and mechanism of baicalin on the formation of plaque after venous bypass. Methods: A rabbit model of atherosclerosis was established. On this basis, an external jugular vein-common carotid artery transplantation model was established. During the experiment, baicalin was used to intervene, and western medicine fenofibrate was used to control the intervention. Through the determination of serum total cholesterol (TC), low density lipoprotein (LDL-C), high density lipoprotein (HDL-C), malondialdehyde (MDA), superoxide dismutase (SOD) To evaluate the effect of baicalin on the regulation of blood lipids, anti-atherosclerosis, anti-oxidation and anti-plaque formation, and explore its mechanism. Results: Compared with western medicine group, the content of serum total cholesterol and low density cholesterol in Chinese medicine group (baicalin) and western medicine group (fenofibrate) were significantly lower than those in western medicine group (P <0.05) ), And in a dose-dependent manner, the higher concentration of baicalin administration, the above effect is more obvious. Conclusion: Baicalin can modulate blood lipid, anti-atherosclerosis, anti-oxidant and inhibit the formation of plaque, thus inhibiting the restenosis of venous bridge and providing powerful force for traditional Chinese medicine treatment of venous bridge restenosis after coronary artery bypass grafting Scientific basis.